Promising colon cancer drugs close to FDA approval

12/4/2003 | Forbes

After successful clinical trials last spring, two new colon cancer drugs are expected to receive FDA approval next year. Imclone Systems' and Bristol-Myers Squibb's Erbitux will be used in patients who already have failed other drug regimens, and Genentech's Avastin will be prescribed for first-line use in patients initially diagnosed with advanced color cancer.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT